Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2018

View Archived Issues

Pancreatic map gives clues to disease

Discovery of a prognostic microRNA for p53-like bladder cancers using ActMiR computation

KinoPharma establishes collaboration for research in Alzheimer's disease

GSK-701: a first-in-class clinical antimalarial candidate with good oral bioavailability

Virus-based vaccine shows promise as candidate for Zika virus

SLC10A7 gene mutations implicated in skeletal dysplasia

Finally, the best of both worlds? Bifunctional opioid agonist fights pain, and addiction

Phase II PANTHEON results for neladenoson bialanate in heart failure patients reported

Astellas Pharma discloses KRAS Gly12Cys mutant inhibitors

Merck & Co. optimizes newly discovered IDO1 inhibitors

Duzallo, a fixed-dose combination therapy for gout, approved in Europe

Low levels of CDKN1C indicate LV dysfunction risk in women after myocardial infarction

Positive XEN-1101 pharmacodynamic data from Xenon's phase Ib TMS study

Lenvima capsules approved for first-line treatment of HCC in South Korea

Vertex and Genomics collaborate to advance discovery of precision medicines

Sophiris Bio announces update on phase IIb trial in localized prostate cancer

Poxel acquires DRX-065 and portfolio of additional deuterated drug candidates

First patient dosed in phase II clinical trial in Duchenne muscular dystrophy

Blincyto approved for use in pediatric patients with Ph- relapsed or refractory B-cell precursor ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.